$5.84 $0.01 (0.2%)

03:04 PM EST on 02/19/20

MediciNova, Inc. (NASDAQ:MNOV)

CAPS Rating: 1 out of 5

Acquire & dvlp high-qlty small molecule therapeuts

Current Price $5.84 Mkt Cap $256.3M
Open $5.89 P/E Ratio 0.00
Prev. Close $5.83 Div. (Yield) $0.00 (0.0%)
Daily Range $5.77 - $5.97 Volume 27,780
52-Wk Range $5.58 - $7.09 Avg. Daily Vol. 77,130

Caps

How do you think NASDAQ:MNOV will perform against the market?

Add Stock to CAPS Watchlist

All Players

13 Outperform
8 Underperform
 

All-Star Players

3 Outperform
7 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:MNOV Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.54)
Submitted February 15, 2014

Add MediciNova to the NASH bandwagon. In January the company claimed positive results from preclinical testing of MN-001 small molecule 5-LO pathway inhibitor in a mouse model of NASH and they state they are preparing for a phase II trial in humans.… More

zzlangerhans (99.54)
Submitted February 25, 2016

So far in 2016, MediciNova has been proving that hope is not dead for the small cap biopharma sector. Or, in 2016, MediciNova has been proving that the sector downturn hasn't made it impossible to manipulate low float stocks upward to facilitate a… More

Recent Community Commentary

Read the most recent pitches from players about MNOV.

Recs

0
Member Avatar SmartAce (99.97) Submitted: 2/3/2020 1:22:21 PM : Underperform Start Price: $5.90 NASDAQ:MNOV Score: +5.68

A rival dad is mad because on his Facebook post about his Super Bowl party I asked if he was going to have store brand ketchup again this year.

Recs

0
Member Avatar TerryHogan (99.97) Submitted: 10/4/2018 2:59:20 AM : Underperform Start Price: $12.56 NASDAQ:MNOV Score: +69.89

Continual share dilution, and zero revenue. I think people are buying this as a lottery ticket, thinking they're going to cure ALS and become the next Pfizer, or be bought. I think the only way it's like a lottery ticket is that your expected outcome is a loss. Best thing you can say about this company is that they aren't burning cash too quickly, but that's also probably the worst thing you can say about them, because I while I ain't no molecular biologist (I used to be one though - true story!) I don't think drug discovery and development is cheap.

Recs

0
Member Avatar LifeScientist (25.19) Submitted: 3/2/2016 7:38:22 PM : Underperform Start Price: $6.06 NASDAQ:MNOV Score: +74.13

good thesis for upcoming short

Leaderboard

Find the members with the highest scoring picks in MNOV.

Score Leader

portefeuille

portefeuille (98.63) Score: +180.17

The Score Leader is the player with the highest score across all their picks in MNOV.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
portefeuille2 98.98 4/11/2014 10/31/2019 Outperform 5Y $2.00 +191.75% +86.31% +105.44 0 Comment
portefeuille3 97.41 4/11/2014 Outperform 5Y $2.00 +191.75% +86.59% +105.16 0 Comment
ababrmon 90.40 3/24/2014 Outperform 1Y $2.12 +175.24% +81.83% +93.40 0 Comment
gunda7907 < 20 3/21/2014 Outperform 5Y $2.16 +170.14% +80.47% +89.67 0 Comment
zzlangerhans 99.54 2/25/2016 Underperform 1Y $6.70 -12.87% +75.27% +88.14 1 Comment
stainsolution < 20 3/12/2014 Outperform 5Y $2.19 +166.44% +81.17% +85.27 0 Comment
LifeScientist 25.19 3/3/2016 Underperform 3M $6.06 -3.71% +70.42% +74.13 1 Comment
TerryHogan 99.97 10/4/2018 Underperform 5Y $12.56 -53.54% +16.34% +69.89 1 Comment
deepcrisis 99.51 7/9/2018 Underperform 5Y $8.47 -31.11% +22.50% +53.61 0 Comment
dollarsandcents1 < 20 10/2/2015 Outperform 5Y $2.79 +109.14% +77.72% +31.42 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for MNOV.